Summary
The 8 th Meeting of the European Forum on Antiphospholipid Antibodies was an important setting for timely, in-depth discussions concerning the antiphospholipid syndrome (APS) and it provided an opportunity for European investigators to exchange information with colleagues from the USA who have taken important steps forward in this field. The future governance of the European Forum was also clearly outlined by the forum coordinator. During the first part of the meeting, the physiopathology of thrombotic and obstetric APS as well as the possible implications of adjuvant vaccines in the pathogenesis of APS were assessed and discussed. The ongoing and future projects of the forum as well as laboratory and clinical aspects of APS were also addressed. The program included two guided poster sessions and 11 oral presentations. A surprisingly large number of participants (n ¼ 271) joined from 23 different European and extra-European countries and an unexpected number of young researchers participated for the 'young investigator awards'. A lecture on the University of Padua Medical School over the centuries and its role in the development of modern medicine along with a singular social program including a guided tour of Giotto's Scrovegni Chapel gave the meeting an exceptionally wellrounded program.
The forum was an important setting for timely discussions concerning latest developments with regards to APS. It also provided European investigators with an opportunity to exchange information with colleagues from the USA who have recently taken important steps forward in this field. The first two sections of the issue, in fact, refer to the activities carried out by the Antiphospholipid Syndrome Alliance for Clinical Trials International Networking (APS ACTION) and to the summary of conclusions reached at the 13 th International Congress on Antiphospholipid Antibodies held in Galveston, Texas, in April 2010. These presentations were followed by that of the coordinator of the European Forum, Ricard Cervera, who outlined the group's future governance. The physiopathology of thrombotic and obstetric APS and the possible implications of adjuvant vaccines in the pathogenesis of APS were then reviewed by three eminent experts in the field.
At the conclusion of the first day sessions, a lecture on the University of Padua Medical School over the centuries and its role in the development of modern medicine was presented by Dr Piero Marson, a respected physician who is also specialized in medical history. He traced the history of the University of Padua's foundation explaining how it all began when a group of students broke away from the University of Bologna in 1222 over a dispute concerning academic freedom. The group migrated to Padua where they founded a new university which, like Bologna's, was student-controlled with students electing the professors and fixing their salaries. The University of Padua was tolerant and liberal; enrolling Protestant and Jewish students as well as women. Elena Lucrezia Cornaro Piscopia, in fact, became the first woman in the world to receive a Doctorate of Philosophy in 1678. The 15 th and 16 th centuries can be considered the School of Medicine's golden era when important scientists, anatomists and physicians such as Galileo Galilei, Andreas Vesalius, William Harvey, Gabriele Falloppio and Girolamo Fabrici d'Acquapendente taught there. Students from all parts of Europe came to study, making the city an international centre of culture and sciences. Padua, thus, became the Renaissance scientific centre of Europe just as Florence was for art. The morning of the second day was dedicated to updating the participants on the forum's ongoing multicentre studies and on new forum projects, and the afternoon as well as the third day sessions focused on laboratory and clinical aspects of APS. Two round tables were held: the first on the standardization of conventional aPL assays and the second on testing for other aPL antibodies including antiphosphatidylethanolamine, antiprothrombin, antiphosphatidylserine/prothrombin complex and anti domain I and IV-V ELISA antibodies. Clinical reports focusing on the secondary prevention of both thrombosis and obstetric complications in APS and risk factors for pregnancy failure were reviewed. New anticoagulants and innovative therapies for unresponsive APS were outlined. Presentations on the primary prevention of thrombosis in aPL carriers were also delivered. Two guided poster sessions were held during the second day and a session dedicated to oral presentations was included in the third day of the program.
There was a surprisingly large number of participants (n ¼ 271) coming from 20 different European and extra-European countries (including the USA, Argentina, and the Bahamas) just as there was an unexpected number of applications for the 'young investigator awards'. The four winning presentations were of a high scientific level and have been dedicated appropriate space in this special issue of LUPUS.
One of the most impressive highlights of the meeting was the tribute paid to Dr Marie Claire Boffa, the founder and the soul of the European Forum. Dr Cervera retraced the forum past largely influenced by Dr Boffa's intuitive, dedicated commitment whilst in the background a song by Edith Piaf, considered to be France's national popular singer, played softly. The social program took advantage of the city's historical/cultural/artistic heritage: on the evening of the first day all participants were accompanied on a guided tour of Giotto's singular Scrovegni Chapel. The social dinner, taking place in a 16th century Palazzo overlooking one of the largest squares in Europe, was enlivened by a string quartet playing classical music.
Taken together, as affirmed by many of the participants, the meeting was a well-rounded, unforgettable experience.
It is with great pleasure that we have accepted the invitation from Dr Maria Laura Bertolaccini, Dr Munther Khamashta and Professor Graham Hughes to publish the proceedings of the 8th European Forum on Antiphospholipid Antibodies in this special issue of LUPUS.
